Immunotherapy in Allergic Rhinitis

Abstract

Allergic rhinitis is an immunologic disorder that develops in individuals who have produced allergen-specific immunoglobulin E in response to environmental exposures (most commonly to pollens, animal dander, insect debris, and molds). For patients with a severe allergy that is not responsive to environmental controls and pharmacotherapy or for those who do not wish to use medication for a lifetime, immunotherapy may be offered. Specific immunotherapy as practiced since hundred years in Western Europe and the USA. Different routes for specific immunotherapy have been evaluated, such as the subcutaneous, sublingual, oral, nasal, bronchial, and intra-lymphatic, the first 2 of these routes being the most commonly used today in clinical practice. In this article, subcutaneous and sublingual immunotherapy in allergic rhinitis is reviewed.

Keywords

• Immunotherapy, Allergic Rhinitis

References

1. Strachan D, Sibbald B, Weiland S, Aït-Khaled N, Anabwani G, Anderson HR et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997;8:161– 76.
2. Bjorksten B, Clayton T, Ellwood P, Stewart A, Strachan D.Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood. 2008;19:110– 24. Allergy Immunol
3. Linneberg A, Nielsen NH, Frolund L, Madsen F, Dirksen A, Jorgensen T. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy 2001; 57:1048–52.
4. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane (1):CD001936. SystRev 2007;
5. Bousquet J, Schünemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C et al. Allergic rhinitis and its impact on asthma. achievements in 10 years and future needs. J Allergy Clin Immunol 2001;108:147–334.
6. Bufe A, Roberts G. Specific immunotherapy in children. Clin Exp Allergy 2011;41:1256-62.
7. Bousquet J, Lockey R, Malling HJ, Alvarez- Cuesta E, Canonica GW, Chapman MD Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 1998;81:401–5.
8. Cox L, T.Li James, Lockey R, Nelson H, Bernstein D, Bernstein L, et al. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007;120:25–85.

9. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143– 78
10. Passalacqua G, Compalati E, Canonica GW. Advances in allergen-specific immunotherapy. Curr Drug Targets 2009;10:1255–62
11. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, et al. Sub- lingual organization position paper 2009. Allergy 2009; 64:1–59 world allergy
12. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:1572–3.
13. Freeman J. Vaccination against hay fever: report of results during the first three years. Lancet 1914;1:1178 14. AJ Frew immunotherapy. Allergy 2011;41:1221-5. years of Experimental Clinical &
14. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007.
15. Bufe A, Eberle P, Franke-Beckmann E, Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009; 123:167–73.
16. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beamuont O,et al. Efficacy and safety of 5- grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123:160–6.
17. Drachenberg KJ, Wheeler AWSUP, Horak F. Short-course specific immunotherapy (SIT) adjuvanted by monophosphoryl lipid A (MPL). A multi-centre, doubleblind, placebo-controlled study. Allergy 2000; 55:142.
18. Lockey RF, Benedikt LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987; 79:660–677.
19. Frew AJ, Powell RJ, Corrigan CJ, Durham SR; UK Immunotherapy Study Group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319–28.
20. Khinchi MS, Poulsen LK, Carat F, André C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen specific immunotherapy: a randomized, placebocontrolled, double-blind, double-dummy study. Allergy 2004;59:45–53.
21. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003;112: 915-22.
22. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004;172:3252-9.
23. Van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J,et al. Blocking antibodies vaccination prevent the activation of CD4 + T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999;163:2944-52.
24. Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008; 121:1120-5.
25. Daeron M, Malbec O, Latour S, Arock M, Fridman WH. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995;95:577-85
26. Akdis M, Akdis CA. Mechanisms of allergen- specific immunotherapy. J Allergy Clin Immunol 2007; 119:780–9.
27. Roder E, Berger MY, de Groot H, Van Wijk RG. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol 2008;19: 197–207.
28. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102:98-106.
29. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+ FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007;110:2983-90.
30. Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, et al. Relation of CD4 + CD25 + regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363:608-15.
31. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, et al. Immune responses in healthy and allergicindividuals are characterized by a fine balance between allergen- specific T regulatory 1 and T helper 2 cells. J Exp Med 2004;199:1567-75.
32. Francis JN, Till SJ, Durham SR. Induction of IL- 10 (+) CD4 (+) CD25 (+) T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111:1255-61.
33. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, et al. IL-10 and TGF- beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific 2003;33: 1205-14. Eur J Immunol
34. Mamessier E, Birnbaum J, Dupuy P, Vervloet D, Magnan A. Ultra-rush VIT induces differential T cell activation and regulatory patterns according to the severity of allergy. Clin Exp Allergy 2006;36:704-13.
35. Radulovic S, Jacobson MR, Durham SR, Nouri- Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4(+) CD25(+) cells in the nasal 2008;121:1467-72. Allergy Clin Immunol
36. Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM, et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 2007;178: 4658-66.
37. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn- Schmid B, Ebner C. Sublingual immunotherapy induces IL-10- producing T regulatory tolerance, and immune deviation. J Allergy Clin Immunol 2007;120:707-13 T-cell
38. Akoum H, Tsicopoulos A, Vorng H, Wallaert B, Dessaint JP, Joseph M, et al. Venom immunotherapy modulates interleukin- 4 and interferon-gamma messenger RNA expression of peripheral 1996;87:593-8. Immunology
39. Magnan A, Marin V, Mely L, Birnbaum J, Romanet S, Bongrand P, et al. Venom immunotherapy induces monocyte activation. Clin Exp Allergy 2001;31:1303-9.
40. Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DY. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996;98:225-31.
41. Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from Th2 to Th1 in T-cell clones specific for Phl p1, a major grass pollen allergen. Clin Exp Allergy 1997;27:1007- 15.
42. Varney VA, Tabbah K, Mavroleon G, Frew AJ. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin Exp Allergy 2003; 33: 1076–82.
43. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010;8:CD001186.
44. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite: a doubleblind study. Allergol Immunopathol. 1990;18:277–284.
45. Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy. 1986; 16:483–491.
46. Wilson DR, Torres-Lima M, Durham S. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy. 2005; 60:4–12.
47. Penagos M, Compalati E, Tarantini F, Baena- Cagnani R, Huerta J, Passalacqua G,et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3–18 years of age: a meta analysis of randomized placebo-controlled, double blind trials. Ann Allergy Asthma Immunol. 2006;97:141–148.
48. Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S,et al. Long-term clinical efficacy rhinoconjunctivitis after treatment with SQ- standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010;125:131–138.
49. Miceli Sopo S, Onesimo R, Giorgio V, Fundaro C. Specific oral tolerance induction (SOTI) in pediatric age: clinical research or just routine practice? Pediatr Allergy Immunol 2010; 21:446–9.
50. Winther L, Arnved J, Malling HJ, Nolte H, Mosbech H. Side-effects of allergenspecific immunotherapy. A prospective multi-centre study. Clin Exp Allergy 2006; 36:254–60. U, 52. Lüderitz-Püchel
51. Keller-Stanislawski B,
52. Haustein D. Neubewertung des Risikos von Test
53. und Therapieallergenene. Eine Anaylse der UAW-medlungen
54. Bundesgesundheitsbl Gesundheitsforsch 2003; 44:709–18. 1991 bis 2000.
55. Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DY. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996;98:225-31.
56. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987;79:660-77.
57. Tabar AI, Garcia BE, Rodriguez A, Olaguibel JM, Muro MD, Quirce S. A prospective safety- monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993; 48:450-3.
58. Lombardi C, Gargioni S, Melchiorre A, Tiri A, Falagiani P, Canonica GW, et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. Allergy 2001;56:989-92.
59. Rienzo VD, Minelli M, Musarra A, Sambugaro R, Pecora S, Canonica WG, et al. Post-marketing survey immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005;35:560-4.
60. Passalacqua G, Durham SR. Allergic rhinitis and its impact immunotherapy. J Allergy Clin Immunol 2007; 119:881-91. update: allergen
61. Larsen TH, Poulsen LK, Melac M, Combebias A, Andre C, Malling HJ. Safety and tolerability of grass pollen tablets in sublingual immunotherapy e a phase-1 study. Allergy 2006; 61:1173-6.
62. Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy 2006; 61:1235.
63. Hsu NM, Reisacher WR. A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy. Int Forum Allergy Rhinol 2012;2:280.
64. Vita D, Caminiti L, Ruggeri P, Pajno GB. Sublingual immunotherapy: adherence based on timing and monitoring control visits. Allergy 2010; 65:668.
65. Pajno GB, Caminiti L, Crisafulli G, Barberi S, Landi M, Aversa T et al. Adherence to sublingual immunotherapy in preschool children. Pediatr Allergy Immunol 2012; 23:688. 64. Senna G, Lombardi C, Canonica GW, Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' Immunol 2010; 126:668. J Allergy Clin
66. Kiel MA, Röder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Mölken MP. Real-life compliance and persistence among users of subcutaneous immunotherapy. J Allergy Clin Immunol 2013; 132:353. sublingual allergen